Analysis Tools
immune system
|
• following exposure to MOG35-55, mice do not lose body weight
• no mice exhibit clinical signs of EAE by day 14, in contrast, 9 of 11 wild-type mice exhibit clinical signs
• by day 30, 5 of 10 mice exhibit mild clinical signs of EAE; all wild-type mice exhibit signs of severe EAE
|
|
• following LPS exposure, mice regain almost 90% of pre injection body weight by day 9
• 6 of 13 mice exhibit minimal swelling by day 7 in contrast to extensive swelling in controls
• 2 of 7 mice exhibit 1 or 2 affected joints by histopathological analysis, in contrast, 7 of 7 wild-type exhibit signs of disease with more than 3 or 4 joints affected
• no mice exhibit redness, marked swelling or ankylosis
• no mice develop inflammatory cell infiltrates, synovial hyperplasia, cartilage necrosis, bone erosion or fibrosis
• mice have decreased levels of the cytokines G-SCF and IL6 on day 7 as compared to controls
|
|
• following exposure to imiquimod cream, mice develop epidermal thickening and some cellular infiltration into the dermis, however, response is significantly less than in wild-type mice
• mice do not develop epidermal neutrophilic abscesses or pustules
• controls develop severe epidermal hyperplasia, parakeratosis, and dermal inflammation
|
skeleton
|
• following LPS exposure, mice regain almost 90% of pre injection body weight by day 9
• 6 of 13 mice exhibit minimal swelling by day 7 in contrast to extensive swelling in controls
• 2 of 7 mice exhibit 1 or 2 affected joints by histopathological analysis, in contrast, 7 of 7 wild-type exhibit signs of disease with more than 3 or 4 joints affected
• no mice exhibit redness, marked swelling or ankylosis
• no mice develop inflammatory cell infiltrates, synovial hyperplasia, cartilage necrosis, bone erosion or fibrosis
• mice have decreased levels of the cytokines G-SCF and IL6 on day 7 as compared to controls
|
